Close Menu

Precision Oncology News: Breaking News

The study comparing eprenetapopt plus azacitidine to azacitidine alone showed that the experimental combo did not significantly extend remission rates.

The combined solution will give health systems access to real-time genetics expertise so they can integrate genetic test results into patients' care.  

The company submitted data on amivantamab as a treatment for metastatic non-small cell lung cancer patients with EGFR exon 20 insertion mutations.

Zai Lab will pay Cullinan $20 million upfront to license the drug in Greater China and could pay up to $211 million in future milestones and royalties.

The Japanese Ministry of Health, Labor, and Welfare approved the molecularly defined indications based on data from the PAOLA-1, PROfound, and POLO trials.

The company closed a $110 million private investment in public equity financing and announced a new financing for $15 million.

A data monitoring committee said that BMS's immunotherapy plus standard of care would not improve overall survival in MGMT-methylated brain cancer patients.

Researchers aim to evaluate the safety and tolerability of the CD19-specific T cells manufactured using Ziopharm's Rapid Personalized Manufacturing process.

AmoyDx will develop and seek regulatory approval in China for a lung cancer PCR panel to be used with Merck's MET inhibitor tepotinib.

A case series in partnership with My Gene Counsel to highlight the challenges genetics professionals and oncologists are grappling with as genetic testing is increasingly used in patient care.

The Phase I clinical trial will assess Mustang's autologous, IL13Rα2-directed CAR T-cell therapy, MB-101, in patients with leptomeningeal brain tumors.

Bayer will offer Veracyte's Afirma Xpression Atlas to identify underlying drivers in tumors of late-stage or metastatic thyroid cancer patients resistant to radioactive iodine therapy.

Earlier this year, Novigenix and collaborators were awarded up to €1 million to develop a blood-based multi-omics colorectal cancer assay.

An independent data monitoring committee recommended terminating the study and Astellas has stopped enrollment after the drug failed to meet its primary endpoint.

The submission follows recently presented study data showing that the vast majority of patients on ciltacabtagene autoleucel responded to the therapy.

A range of drugs from Agios' cancer pipeline will be transferred to Servier, including two commercial drugs Tibsovo and Idhifa.

Servier will have an exclusive option to research, develop, and commercialize products for up to three of the targets identified by Celsius.

The agency made its decision based on data showing adjuvant Tagrisso decreased the risk of cancer recurrence or death by 80 percent compared to placebo. 

The firm will use the contract to further develop its technology capable of matching cancer patients to trials based on molecular and clinical information.

The Universities of Southampton and Leeds will lead the project with participation from Johnson & Johnson, Roche, Oncimmune, BC Platforms, Inivata, and NHS England.

If approved, the drug would be the first targeted therapy available to treat patients with NSCLC harboring KRAS G12C mutations.

The autologous treatment received conditional approval for relapsed or refractory mantle cell lymphoma patients based on results of the ZUMA-2 trial.

Sema4 will use its next-generation sequencing testing services to identify patients with solid tumors harboring NRG1 fusions for Merus' Phase I/II drug trial.

The agency approved the drug based on data from the SOPHIA trial, which showed Margenza improved progression-free survival over Herceptin.

The Phase III Keynote-775 study has shown that the combination improves overall and progression-free survival compared to chemotherapy.